TIME COURSE OF TREATMENT-RELATED ADVERSE EVENTS (TRAES) DURING DOSTARLIMAB THERAPY IN THE GARNET TRIAL

被引：0

作者：

Pothuri, Bhavana ^{[1
,2
]}

Berton, Dominique ^{[3
,4
]}

Moreno, Victor ^{[5
]}

Oaknin, Ana ^{[6
]}

Perez, Jose Manuel Trigo ^{[7
]}

Curigliano, Giuseppe ^{[8
,9
]}

Ellard, Susan ^{[10
]}

Pikiel, Joanna ^{[11
]}

Banerjee, Susana ^{[12
,13
]}

Barretina-Ginesta, Maria-Pilar ^{[14
]}

Miller, Rowan ^{[15
]}

Tinker, Anna ^{[16
]}

Jewell, Andrea ^{[17
]}

Plummer, Ruth ^{[18
]}

Joly, Florence ^{[19
]}

Veneris, Jennifer ^{[20
]}

Duan, Tao ^{[20
]}

Andre, Thierry ^{[21
,22
]}

机构：

[1] NYU Langone Hlth, Perlmutter Canc Ctr, Gynecol Oncol Grp GOG, New York, NY USA

[2] NYU Langone Hlth, Perlmutter Canc Ctr, Dept Obstet Gynecol, New York, NY USA

[3] Ctr Rene Gauducheau, GINECO, St Herblain, France

[4] Ctr Rene Gauducheau, Inst Cancerol Ouest, St Herblain, France

[5] Fdn Jimenez Diaz Hosp, START Madrid FJD, Madrid, Spain

[6] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[7] Hosp Virgen Victoria IBIMA, Med Oncol Dept, Malaga, Spain

[8] IRCCS, European Inst Oncol, IEO, Div Early Drug Dev Innovat Therapies, Milan, Italy

[9] Univ Milan, Milan, Italy

[10] BC Canc Kelowna, Kelowna, BC, Canada

[11] Reg Ctr Oncol, Gdansk, Poland

[12] Royal Marsden NHS Fdn Trust, London, England

[13] Inst Canc Res, London, England

[14] Hosp Univ Dr J Trueta, Inst Catala Oncol, Girona, Spain

[15] UCL, St Bartholomews Hosp London, London, England

[16] BC Canc, Vancouver, BC, Canada

[17] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA

[18] Newcastle Univ, Med Sch, Northern Inst Canc Res, London, England

[19] Ctr Francois Baclesse, Med Oncol Dept, Caen, France

[20] GlaxoSmithKline, London, England

[21] Sorbonne Univ, Paris, France

[22] St Antoine Hosp, Paris, France

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷

关键词：

D O I：

10.1136/jitc-2021-SITC2021.370

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

370

引用

页码：A398 / A398

页数：1

共 50 条

[1] Treatment-related adverse events (TRAEs) occurring during dostarlimab therapy in the GARNET study
Andre, T.
Berton, D.
Oaknin, A.
Moreno Garcia, V.
Curigliano, G.
Trigo, J.
Barretina-Ginesta, M-P.
Ellard, S.
Tinker, A. V.
Miller, R.
Pikiel, J.
Boni, V.
Cresta, S.
Pothuri, B.
Perez, D. Roda
Drew, Y.
Veneris, J.
Im, E.
Banerjee, S.
ANNALS OF ONCOLOGY, 2021, 32 : S845 - S846
[2] TIME COURSE OF ADVERSE EVENTS DURING DOSTARLIMAB TREATMENT IN PATIENTS WITH RECURRENT OR ADVANCED ENDOMETRIAL CANCER IN THE GARNET TRIAL
Oaknin, A.
Gilbert, L.
Tinker, A.
Guo, W.
Im, E.
Pothuri, B.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A74 - A74
[3] The time course of adverse events during dostarlimab treatment in mismatch mutation repair deficient and proficient endometrial cancer patients in the GARNET trial
Hanker, L.
Oaknin, A.
Gilbert, L.
Tinker, A.
Guo, W.
Im, E.
Pothuri, B.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 240 - 241
[4] The time course of adverse events (AEs) during dostarlimab treatment in mismatch mutation repair deficient (dMMR) and proficient (MMRp) endometrial cancer (EC) patients in the GARNET trial
Banerjee, Ashish
Oaknin, Ana
Gilbert, Lucy
Guo, Wei
Im, Ellie
Pothuri, Bhavana
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 162 - 162
[5] Estimated costs of treatment-related adverse events (TRAEs) for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the checkmate 141 trial
Venkatachalam, M.
Bobiak, S.
Shaw, J. W.
Santi, I.
Contente, M.
Korytowsky, B.
Stenehjem, D. D.
ANNALS OF ONCOLOGY, 2017, 28
[6] ESTIMATED COSTS OF TREATMENT-RELATED ADVERSE EVENTS (TRAES) FOR RECURRENT OR METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN THE CHECKMATE 141 TRIAL IN SPAIN
Suarez Rodriguez, J.
Venkatachalam, M.
Shaw, J. W.
Contente, M.
Polanco Sanchez, C.
VALUE IN HEALTH, 2019, 22 : S448 - S448
[7] Management of hepatorenal syndrome and treatment-related adverse events
Peluso, Lorenzo
Savi, Marzia
Coppalini, Giacomo
Veliaj, Deliana
Villari, Nicola
Albano, Giovanni
Petrou, Stephen
Pace, Maria C.
Fiore, Marco
CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (07) : 1155 - 1162
[8] MANAGEMENT OF IMMUNE-RELATED ADVERSE EVENTS IN PATIENTS WITH SOLID TUMORS TREATED WITH DOSTARLIMAB IN THE GARNET STUDY
Banerjee, Susana
Andre, Thierry
Berton, Dominique
Oaknin, Ana
Moreno, Victor
Trigo, Jose
Curigliano, Giuseppe
Tinker, Anna
Boni, Valentina
Pilar Barretina-Ginesta, Maria
Pikiel, Joanna
Pothuri, Bhavana
Mirza, Mansoor
Panovcova, Petra
Duan, Tao
Dabrowski, Christine
Zografos, Eleftherios
Veneris, Jennifer
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A27 - A28
[9] Managing treatment-related adverse events associated with Alk inhibitors
Rothenstein, J. M.
Letarte, N.
CURRENT ONCOLOGY, 2014, 21 (01) : 19 - 26
[10] Contribution of pharmacoepidemiological studies to the evaluation of treatment-related adverse events
Suissa, Samy
JOINT BONE SPINE, 2006, 73 (06) : 627 - 628

← 1 2 3 4 5 →